Search Results 801-810 of 16921 for Amphotericin B

  1. A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer - Mayo Clinic

    Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (i.e., patients immunized against hepatitis B). In some ...

  2. Niemann Pick Clinical Trials - Mayo Clinic Research

    The purpose of this study is to establish the natural history of the 3 diseases - Niemann-Pick Type A, B, and C (their characteristics, management and outcomes) ...

  3. Critical Care - Doctors - Mayo Clinic

    Jeffrey B. Peel, M.D.. Neurocritical Care Specialist. Jacksonville, FL. Areas of focus: Lumbar puncture, ...

  4. Gastroenterology and Hepatology - Doctors - Mayo Clinic

    B. Pediatrician; Pediatric Gastroenterologist; Pediatric Transplant Hepatologist. Rochester, MN ...

  5. Clinical trials - Oncology (Medical)

    Also, we will evaluate whether the peripheral blood immune cell function is different in B/AA prostate cancer patients with metastatic disease as compared with ...

  6. Arthritis - Doctors and departments - Mayo Clinic

    Amir B. Orandi, M.D.. Pediatric Rheumatologist. Rochester, MN ...

  7. Publications - Bradley F. Thompson, M.D. - Mayo Clinic

    Thompson B, Jenkins T, Sanchez JP, Frederick M, Posligua-Alban A, Barbosa NS. Melanoma: Does It Present Differently in Darker Skin Tones? MedEdPORTAL. 2023 ...

  8. General Internal Medicine - Doctors - Mayo Clinic

    Narrow your search · Find a doctor whose last name begins with the letter A A · Find a doctor whose last name begins with the letter B B · Find a doctor whose last ...

  9. Charles F. Abboud, M.B. - Doctors and Medical Staff - Mayo Clinic

    Disorders of the hypothalamus-pituitary unit; Disorders of the adrenal glands and gonads; Undergraduate and graduate education; Continuing medical education ...

  10. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...